5 articles with AlzProtect
Alzprotect Strengthens Its Intellectual Property Portfolio for Its First-in-Class Clinical Stage Drug Ezeprogind
Alzprotect, a biopharmaceutical company developing therapeutic solutions for neurodegenerative diseases announces that the United States Patent and Trademark Office has recently granted patent number US 10,772,884 concerning the therapeutic uses of its first-in-class clinical stage drug Ezeprogind in the treatment of tauopathies.
9/21/2020It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies.
Alzprotect Forges Ahead with First Patients Enrolled in Phase 2a Study in Progressive Supranuclear Palsy (PSP)
ALZPROTECT announced the recruitment of the first 5 patients to participate in its phase 2a clinical trial with its drug candidate AZP2006 in Progressive Supranuclear Palsy, an orphan disease for which the company has been granted with the “orphan drug” status by the Food and Drug Administration and European Medicines Agency.
AlzProtect: The American FDA Has Granted AZP2006 the Orphan Drug Designation for the Treatment of Progressive Supranuclear Palsy (PSP)